Since the Trump Administration change in January 2025, FDA has undergone a period of transition, marked by organizational restructuring and shifts in priorities; yet rare disease pathways have been a consistent priority for FDA leadership. The new administration has signaled its interest in incentivizing drug sponsors to develop innovative therapies for rare diseases. Taking advantage of these programs and FDA's prioritization of rare diseases is a key opportunity for drug developers in the disease space.

The complexity of rare disease drug development has long presented challenges for FDA in incentivizing and overseeing therapies for rare diseases from development to approval. The typical ("gold standard") randomized controlled trial is an expensive and challenging scientific endeavor for these types of drugs because there are so few patients available to participate. While FDA has often exercised its ability to use regulatory flexibility in evaluating the type and amount of evidence in applying approval standards, sponsors have continued to be stymied by pitfalls in development. Consequently, many rare disease drugs never make it through development, let alone to market.

FDA Commissioner Marty Makary has prioritized lowering barriers in the rare disease space. In his first public interview as commissioner, Dr. Makary announced a plausible mechanism pathway through which sponsors could seek approval. In November 2025, he explained the new pathway through a publication in a medical journal, and affirmed it is intended for "bespoke, personalized therapies" that "challenge traditional models of drug and biologic development."

The administration has also developed the FDA Commissioner's National Priority Voucher pilot program, which permits selected companies to access additional benefits, including two-month review, enhanced communications, and rolling review. Further, late in 2025, FDA stated that it will lower the number of clinical trials required to approve new drugs. Going forward, FDA will default to one trial, though it may still require two trials in some cases. This adds to the suite of designations and programs that Congress and FDA have developed to help speed therapies to market to meet unmet medical needs, including longstanding Fast Track, Breakthrough Therapy, and Accelerated Approval, as well as Regenerative Medicine Advanced Therapy and Advanced Manufacturing Technologies designations.

Finally, in January 2026, FDA renewed its commitment to flexibility in overseeing chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies. These complex biological products continue to be critical in advancing treatments of rare genetic conditions, and FDA's announcement signals the agency's interest in increasing the efficiency of developing these products, which often face program-halting CMC issues.